Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is a quaternary ammonium compound acting as a selective peripheral anticholinergic agent (muscarinic receptor antagonist). It is primarily utilized for its antispasmodic effects on smooth muscle.
## Primary Indications
* Symptomatic relief of gastrointestinal spasms (irritable bowel syndrome, enteritis).
* Adjunctive therapy in the treatment of peptic ulcer disease and gastritis.
## Adult Dosing
* **Standard dose:** 10 mg to 20 mg orally, three to four times daily.
* **Maximum dose:** 80 mg per day.
* **Administration:** Typically taken 30 minutes before meals for optimal gastric effect.
## Pediatric Dosing
* **Safety/Efficacy:** Not well established.
* **Off-label/Institutional practice:** Dosing is often weight-based (e.g., 0.1 mg/kg per dose), but use should be restricted to specialized pediatric settings. **Confirm with local institutional protocols** before prescribing.
## Dose Adjustments
* **Renal Impairment:** Use with caution; monitor for increased anticholinergic toxicity as the drug is renally cleared.
* **Hepatic Impairment:** No specific guidelines; use with caution in severe impairment.
* **Geriatric Patients:** Dose titration at the lowest effective level is recommended due to increased sensitivity to anticholinergic side effects (e.g., confusion, urinary retention).
## Contraindications
* Hypersensitivity to the drug or components.
* Glaucoma (narrow-angle).
* Myasthenia gravis.
* Obstructive uropathy (e.g., prostatic hypertrophy).
* Severe ulcerative colitis, toxic megacolon, or paralytic ileus.
* Gastrointestinal obstruction.
## Adverse Effects
* **Common:** Dry mouth, blurred vision, constipation, urinary retention, and tachycardia.
* **Serious:** Confusion, hallucinations (especially in the elderly), increased intraocular pressure, and anaphylaxis.
## Key Drug Interactions
* **Other Anticholinergics:** Synergistic effects increase risk of severe anticholinergic toxicity (e.g., antihistamines, tricyclic antidepressants).
* **Potassium Chloride (oral tablets):** Increased risk of GI mucosal lesions due to decreased gastric motility.
* **Metoclopramide:** Antagonistic effects; avoid concurrent use.
## Monitoring
* Monitor for signs of anticholinergic toxicity (dry mouth, urinary hesitation, CNS changes).
* Assess therapeutic efficacy regarding reduction of abdominal pain/spasms.
* Monitor heart rate in patients with pre-existing cardiac conditions.
## Clinical Pearls
* The quaternary ammonium structure limits central nervous system penetration compared to tertiary amines (like atropine), theoretically reducing the incidence of central side effects.
* Patients should be advised to avoid driving or operating machinery if blurred vision or dizziness occurs.
* Advise patients to maintain adequate fluid intake to mitigate dry mouth and constipation.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and region. Always consult the full current prescribing information (package insert) and hospital-specific formulary guidelines before prescribing or administering any medication.
